Our mission is to advance drug discovery by identifying cell-cell interaction mediators that drive autoimmunity.
The Accelerating Medicines Partnership® (AMP®) Program Autoimmune and Immune-Mediated Diseases (AMP AIM) is a precompetitive partnership that brings together the resources of 20 partner organizations spanning the public, private, and not-for-profit sectors. Managed by the FNIH, the project builds on the success of AMP RA/SLE, which pioneered a transformational approach to dissect how these diseases occur at the individual cell level. AMP RA/SLE advanced new technologies and analytical methods using biopsy and blood samples of diseased tissue from major organs, such as the kidney in lupus and the joints in arthritis. As a result, novel cell populations and pathways have been discovered, suggesting promising new targets for drug development.
Many autoimmune diseases share common inflammatory pathways, comorbidity risks, and even responses to disease-modifying therapies. Although more than 25 million people in the U.S. are affected by these chronic diseases, many remain undertreated and underdiagnosed, and broadly effective treatments are not available. Complex differences in patient genetics and immune function make developing new treatments particularly challenging and complicate patient care.
Reconstructing Autoimmune Pathways
Better tools and biomarkers that define and map these shared and unique immune cell interactions and pathways are critical for the design of new drug targets and effective interventions. The cornerstone of AMP AIM will be the utilization of a suite of next-generation tools and technologies to map how cell types, cell states, and cell-to-cell interactions network to cause inflammation, abnormal function, and tissue injury. The project will generate a comprehensive 3D atlas of integrated single cell multi-omics and identify inflammatory mediators to clarify regulatory mechanisms that govern functions within and between cells.
Private Sector Partners
Public Sector Partners
Bold initiatives, like the AMP AIM program, seek to discover the causes of inflammation and clinical disease, and hold the promise for addressing the significant unmet need for people living with lupus and other autoimmune diseases.
We are excited to be part for the new AMP AIM program in immunological diseases. In the last 6 years the Accelerating Medicine Partnership has delivered valuable insights into the molecular and cellular mechanisms of Rheumatoid Arthritis and Systemic Lupus Erythematosus at single cell resolution.
Director, Inflammation and Immunity[email protected]
For more information about supporting or becoming a partner in this project, please contact
Senior Project Manager, Inflammation and Immunity[email protected]
Director, Strategic Alliances and Advancement[email protected]